MDimune has agreed with China’s NeoCura Bio-Medical Technology (NeoCura), a company specializing in RNA therapeutics, to conduct collaborative studies of cell-derived vesicles (CDV)-based mRNA therapeutic cancer vaccines.

Under the accord, the two companies will jointly seek opportunities of developing mRNA therapeutics delivered by CDVs for therapeutic cancer vaccines.

MDimune first plans to load target mRNA in CDV with NeoCura. After demonstrating initial stability and efficiency through in vitro feasibility in the study, NeoCura will be responsible for the target mRNA design and safety profiling in-vivo feasibility study.

The two partners will seek opportunities for commercialization and licensing agreements once the study draws positive outcomes.

The CDV, the core of this joint research, is produced with the original patented technology of MDMMune. It has demonstrated therapeutic potentials with far greater productivity compared to existing extracellular vesicles such as exosomes.

MDimune is also developing a drug delivery platform called BioDrone that shows potent therapeutic effects with fewer drugs and induce lowered side effects by drug encapsulation techniques.

“NeoCura is committed to enhancing technology to provide innovative anti-cancer vaccines to patients in China and other countries,” NeoCura CEO Yi Wang said. “We are delighted to partner with MDimune to advance mRNA medicine research and bring novel medicines to more cancer patients.”

MDimune CEO Bae Shin-gyu said, “NeoCura is one of China’s top promising biotech companies with the most advanced achievement made in mRNA therapeutic oncology.”

Bae added that the company looks forward to expanding new global business development opportunities through collaboration with NeoCura.